{
    "clinical_study": {
        "@rank": "65679", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Assess the efficacy of 3,4-diaminopyridine in patients with stable chronic demyelinating\n      polyneuropathy."
        }, 
        "brief_title": "Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy", 
        "completion_date": "August 1996", 
        "condition": "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating", 
        "condition_browse": {
            "mesh_term": [
                "Polyradiculoneuropathy", 
                "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are randomly assigned\n      to oral 3,4-diaminopyridine (3,4-DAP) or placebo administered for 4 days.  After a washout\n      of at least 5 days, patients cross to the alternate therapy for 4 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics-- Clinical diagnosis of demyelinating neuropathy, i.e.:\n        Hereditary motor and sensory neuropathy type I Chronic inflammatory demyelinating\n        polyneuropathy meeting American Academy of Neurology AIDS Task Force criteria Multifocal\n        motor neuropathy and conduction block Clinically stable for at least 6 months prior to\n        entry --Prior/Concurrent Therapy-- At least 6 months since change in immunosuppressive\n        dose --Patient Characteristics-- Age: 20 to 80 Hepatic: No predisposition to hepatic\n        disease Renal: No predisposition to renal disease Cardiovascular: No predisposition to\n        cardiac disease Other: No other medical condition affecting neuropathy or study evaluation\n        No predisposition to seizures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": "34", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004939", 
            "org_study_id": "199/11963", 
            "secondary_id": "MAYOC-585"
        }, 
        "intervention": {
            "intervention_name": ",4-diaminopyridine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "3,4-diaminopyridine"
        }, 
        "keyword": [
            "demyelinating neuropathy", 
            "neurologic and psychiatric disorders", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Anthony J. Windebank", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "reference": {
            "PMID": "7776711", 
            "citation": "Russell JW, Windebank AJ, Harper CM Jr. Treatment of stable chronic demyelinating polyneuropathy with 3,4-diaminopyridine. Mayo Clin Proc. 1995 Jun;70(6):532-9."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004939"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "August 1996", 
        "study_design": "Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2001"
    }, 
    "geocoordinates": {}
}